The G20’s top health and health financing experts will assemble in Tokyo on the eve of the Osaka G20 heads […]
SYDNEY (June 18, 2019)—TB Alliance today announced that one million treatment courses of child-friendly tuberculosis (TB) medicines have been ordered
NEW YORK (June 12, 2019)—TB Alliance, a not-for-profit organization leading the development of new, improved and affordable tuberculosis (TB) treatments,
Investigational drug pretomanid, developed by non-profit TB Alliance, is under regulatory review for treatment of extensively drug-resistant tuberculosis and treatment-intolerant
Every year, more than ten million people worldwide contract tuberculosis (TB) and in 2017, 1.6 million people died as a
GENEVA (May 22, 2019) – This week at the Seventy-second World Health Assembly, TB Alliance is joining our partners in global health
Two of TB Alliance’s academic collaborators presented findings from scientific research related to drug-resistant forms of tuberculosis at the American Thoracic
NEW YORK, NY (May 9, 2019)—The National Institute of Allergy and Infectious Diseases (NIAID) has awarded TB Alliance a Center
Joint Statement for Multi-stakeholder Hearing on UHC: Product Development Partnerships “We face a collective challenge in ensuring that everyone—regardless where
We spoke with Karl Hofmann, president and CEO of Population Services International (PSI), to hear about his time serving as
